How do you approach G-CSF use when offering neoadjuvant chemoRT for lower extremity soft-tissue sarcoma?

We don't use concurrent chemo and XRT so it is not an issue for us. I suppose the detrimental effect of XRT on cycling progenitors would depend on the field that is being irradiated. Typical extremity STS may not pose a big risk, but pelvis would.